Prostatic Neoplasms: Clinical Trials

152 trials for Prostatic Neoplasms, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

152 terminated. 152 Phase 1, 63 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1152Terminated 152
Phase 263Terminated 63

Follow Prostatic Neoplasms: new trials by email Literature Review of Prostatic Neoplasms trials Research Report on Prostatic Neoplasms

Trials (filtered) newest first · largest first

All 152 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
AB-3028, a Programmable Circuit T Cell Therapy in Patients With Castration Resistant Prostate Cancer (CRPC)
AB-3028 - Metastatic Castration Resistant Prostate Cancer (mCRPC)
Phase 1 / Phase 2TerminatedArsenal Biosciences, Inc.32026-01-092026-11-16
Neoadjuvant SGLT2 Inhibition in Localized Prostate Cancer
Dapagliflozin - Prostate Cancer, Cancer of Prostate
Phase 1TerminatedWashington University School of Medicine52024-06-042026-06-30
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Abemaciclib, Darolutamide, LHRH agonist/antagonist - Prostatic Neoplasms
Phase 1TerminatedEli Lilly and Company102024-01-122026-06-26
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
VIO-01 - Advanced or Metastatic Solid Tumors, Breast Cancer
Phase 1 / Phase 2TerminatedValerio Therapeutics62024-01-102025-03-17
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
TNG348, Olaparib - Breast Cancer, Ovarian Cancer
Phase 1 / Phase 2TerminatedTango Therapeutics, Inc.72023-12-082024-08-13
A Clinical Study of ONCT-534 in Subjects With Metastatic Castration-resistant Prostate Cancer.
ONCT-534 - Metastatic Castration-resistant Prostate Cancer
Phase 1 / Phase 2TerminatedOncternal Therapeutics, Inc212023-09-202024-12-11
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)
XNW5004, KEYTRUDA® (pembrolizumab) 25 mg/mL Solution for Injection - Carcinoma, Squamous Cell Carcinoma of Head and Neck
Phase 1 / Phase 2TerminatedEvopoint Biosciences Inc.122023-09-202026-07-23
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
Darolutamide, Abemaciclib, GNRH-A Leuprolide Acetate - Metastatic Prostate Cancer, Non-metastatic Prostate Cancer
Phase 1TerminatedPraful Ravi, MB BCHir, MRCP92023-08-092026-10-15
Vudalimab (XmAb20717) in Combination With Standard of Care Treatment in Patients With Metastatic Castration Sensitive Prostate Cancer
Abiraterone, Biospecimen Collection, Bone Scan - Castration-Sensitive Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 1TerminatedEmory University42023-08-032025-09-15
64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
64Cu-SAR-BBN, 67Cu-SAR-BBN - Prostatic Neoplasms, Castration-Resistant
Phase 1 / Phase 2TerminatedClarity Pharmaceuticals Ltd42023-06-152025-08-29
HB-302/HB-301 Therapy in Participants With Metastatic Castration-Resistant Prostate Cancer
HB-302/HB-301 Alternating 2-Vector Therapy - Prostate Cancer Metastatic
Phase 1 / Phase 2TerminatedHookipa Biotech GmbH122023-05-232024-06-12
A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or Ritonavir in Prostate Cancer Patients
Relugolix Pill, Ritonavir, Itraconazole - Prostate Cancer, Prostate Cancer Metastatic
Phase 1TerminatedUniversity of Chicago602023-02-132024-09-19
A Dose Escalation/Expansion Study of MDK-703 in Patients With Advanced or Metastatic Solid Tumors
MDK-703, Checkpoint Inhibitor, Immune - Advanced or Metastatic Solid Tumors
Phase 1 / Phase 2TerminatedMedikine, Inc.262023-02-082024-05-08
A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
[225]-FPI-2059, [111In]-FPI-2058 - Pancreatic Ductal Adenocarcinoma (PDAC), Squamous Cell Carcinoma of Head and Neck
Phase 1Terminated3B Pharmaceuticals GmbH192023-02-072025-08-24
Prime-boost Immunotherapeutic Trial in Men With Biochemical Recurrence After Definitive Local Therapy for Prostate Cancer
ChAdOx1-PCAQ, MVA-PCAQ - Prostate Cancer
Phase 1 / Phase 2TerminatedBarinthus Biotherapeutics222023-01-302025-11-10
Decreasing Dosing Regimens of Abiraterone 500 mg in Men With Prostate Cancer to Find Lowest Recommended Dose.
Abiraterone Oral Tablet, Prednisone tablet, Drug Dairy/Log - Prostate Cancer, Prostate Adenocarcinoma
Phase 1TerminatedUniversity of Chicago502023-01-242025-10-03
A Study of TmPSMA-02 Chimeric Antigen Receptor (CAR) T-cells in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)
TmPSMA-02 - Metastatic Castration-resistant Prostate Cancer
Phase 1 / Phase 2TerminatedTceleron Therapeutics, Inc.12022-09-062023-08-18
Study of Docetaxel Combined with Cirmtuzumab in Metastatic Castration Resistant Prostate Cancer
Cirmtuzumab - Metastatic Castration-resistant Prostate Cancer
Phase 1TerminatedUniversity of California, San Diego62022-06-162024-10-09
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
NUV-868, Olaparib, Enzalutamide - Advanced Solid Tumor, Ovarian Cancer
Phase 1TerminatedNuvation Bio Inc.822022-03-292025-11-06
A Study of EPI-7386 in Combination With Abiraterone Acetate Plus Prednisone, or Apalutamide in Metastatic Castration-resistant Prostate Cancer (mCRPC)
EPI-7386, Abiraterone Acetate, Prednisone or Prednisolone - Prostatic Neoplasms
Phase 1TerminatedJanssen Research & Development, LLC32022-03-232025-02-03

Showing 20 of 152. Sign in to see all of them.

Narrower conditions

Breast Neoplasms (19)  ·  Neoplasm Metastasis (13)  ·  Ovarian Neoplasms (13)  ·  Carcinoma, Non-Small-Cell Lung (9)  ·  Neoplasms (9)  ·  Pancreatic Neoplasms (8)  ·  Lung Neoplasms (7)  ·  Colorectal Neoplasms (5)  ·  Stomach Neoplasms (5)  ·  Urinary Bladder Neoplasms (5)  ·  Carcinoma, Renal Cell (4)  ·  Carcinoma, Transitional Cell (4)  ·  Endometrial Neoplasms (4)  ·  Genital Neoplasms, Male (4)

Broader conditions

Genital Diseases (152)  ·  Male Urogenital Diseases (152)  ·  Urogenital Diseases (151)  ·  Genital Diseases, Male (150)  ·  Neoplasms by Site (149)  ·  Urogenital Neoplasms (149)  ·  Genital Neoplasms, Male (148)  ·  Prostatic Diseases (148)  ·  Neoplasms (143)  ·  Female Urogenital Diseases (26)  ·  Female Urogenital Diseases and Pregnancy Complications (26)  ·  Breast Diseases (20)  ·  Neoplasms by Histologic Type (20)  ·  Skin Diseases (20)  ·  Skin and Connective Tissue Diseases (20)

Interventions

Docetaxel (19)  ·  enzalutamide (13)  ·  Prednisone (12)  ·  abiraterone (8)  ·  Abiraterone Acetate (7)  ·  Magnetic Resonance Spectroscopy (7)  ·  Cyclophosphamide (6)  ·  Leuprolide (6)  ·  bicalutamide (6)  ·  olaparib (6)  ·  Sirolimus (4)  ·  darolutamide (4)  ·  pembrolizumab (4)  ·  Biopsy (3)  ·  Goserelin (3)

Sponsors

National Cancer Institute (NCI) (7)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (6)  ·  Novartis Pharmaceuticals (4)  ·  ESSA Pharmaceuticals (3)  ·  Medical University of South Carolina (3)  ·  NYU Langone Health (3)  ·  OHSU Knight Cancer Institute (3)  ·  Pfizer (3)  ·  Rahul Aggarwal (3)  ·  Roswell Park Cancer Institute (3)  ·  University of Chicago (3)  ·  University of Michigan Rogel Cancer Center (3)  ·  Agennix (2)  ·  Amgen (2)  ·  AvenCell Europe GmbH (2)

Countries

United States (134)  ·  Canada (11)  ·  United Kingdom (10)  ·  Spain (8)  ·  Australia (7)  ·  France (7)  ·  Germany (6)  ·  Belgium (4)  ·  China (4)  ·  Netherlands (4)  ·  Austria (2)  ·  Finland (2)  ·  Italy (2)  ·  Switzerland (2)  ·  Taiwan (2)

Top investigators

Rahul Aggarwal, MD (3)  ·  Christopher Logothetis (2)  ·  Glenn Bubley, MD (2)  ·  Robert B. Montgomery, MD (2)  ·  Samuel Denmeade, MD (2)  ·  William D Figg, Pharm.D. (2)  ·  Aaron Enke (1)  ·  Abhishek Solanki, MD (1)  ·  Adam Crystal, MD, PhD (1)  ·  Adam Dicker, MD (1)  ·  Adam Dicker, MD, PhD (1)

Results publications

PMID 20305636, PMID 20818327, PMID 22326922, PMID 25974235, PMID 31527168, PMID 32897402, PMID 33015525, PMID 33465252, PMID 33744986, PMID 34333820, PMID 35058326, PMID 35110415, PMID 36826464, PMID 36948505, PMID 37902861, PMID 38226958, PMID 38753757, PMID 38885312, PMID 39168098, PMID 39214047, PMID 39473059, PMID 39737899, PMID 39863139, PMID 39990653, PMID 40906325, PMID 41698328, PMID 42820295

NIH funding

2017 (4), 2019 (4), P30CA014089 (2), 2009 (1), 2014 (1), 2018 (1), 2023 (1), N01CM00039 (1), N01CM62202 (1), P30CA015704 (1), P30CA016056 (1), P30CA016672 (1), P30CA036727 (1), P30CA069533 (1), P30CA124435 (1)